Piper Sandler Has Lowered Expectations for InspireMD (NYSE:NSPR) Stock Price

InspireMD (NYSE:NSPR - Get Free Report) had its target price lowered by investment analysts at Piper Sandler from $4.50 to $4.00 in a research report issued to clients and investors on Monday,Benzinga reports. The firm presently has an "overweight" rating on the stock. Piper Sandler's price objective would indicate a potential upside of 69.49% from the stock's previous close.

Separately, StockNews.com assumed coverage on shares of InspireMD in a report on Monday, May 5th. They issued a "sell" rating for the company.

InspireMD Trading Down 0.4%

Shares of NSPR traded down $0.01 during mid-day trading on Monday, reaching $2.36. The company's stock had a trading volume of 38,992 shares, compared to its average volume of 37,431. The stock has a market cap of $72.30 million, a PE ratio of -3.15 and a beta of 0.62. InspireMD has a 52 week low of $2.07 and a 52 week high of $3.80. The company's fifty day moving average price is $2.62 and its two-hundred day moving average price is $2.74.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in NSPR. Affiance Financial LLC increased its stake in shares of InspireMD by 2.9% in the fourth quarter. Affiance Financial LLC now owns 189,122 shares of the company's stock worth $497,000 after buying an additional 5,376 shares during the period. Legato Capital Management LLC purchased a new position in shares of InspireMD in the fourth quarter worth $47,000. Essex Investment Management Co. LLC purchased a new position in shares of InspireMD in the fourth quarter worth $191,000. Renaissance Technologies LLC purchased a new position in shares of InspireMD in the fourth quarter worth $27,000. Finally, Northern Trust Corp increased its stake in shares of InspireMD by 103.7% in the fourth quarter. Northern Trust Corp now owns 48,022 shares of the company's stock worth $126,000 after buying an additional 24,452 shares during the period. 44.78% of the stock is owned by hedge funds and other institutional investors.

About InspireMD

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.